Ehlers

Suzanne Ehlers to join USA for UNHCR as new Executive Director and CEO in January 2023

Retrieved on: 
Monday, December 12, 2022
Water, Ehlers, Refugee, Reproductive health, PAI, Food, Trustee, Filippo Grandi, Peace Corps, Cornell University, Woman, Growth, Multimedia, Safety, Education, Government, UNHCR, Hope, United Nations High Commissioner for Refugees, Organization, Management, Malala Fund

WASHINGTON, Dec. 12, 2022 /PRNewswire/ -- USA for UNHCR, the UN Refugee Agency, announced today that its board of trustees has unanimously chosen Suzanne Ehlers as the organization's next Executive Director and CEO.

Key Points: 
  • WASHINGTON, Dec. 12, 2022 /PRNewswire/ -- USA for UNHCR, the UN Refugee Agency, announced today that its board of trustees has unanimously chosen Suzanne Ehlers as the organization's next Executive Director and CEO.
  • "In the past decade, the number of refugees globally has doubled, and to help them, USA for UNHCR has steadily driven revenue growth and expanded its impact.
  • Suzanne is a systems thinker with experience in grantmaking and a track record of approachable leadership," Wallace continued.
  • Anne-Marie Grey, who has served as Executive Director and CEO since 2014, expressed confidence in the board's choice.

Acer Therapeutics to Participate in March Virtual Investor Conferences

Retrieved on: 
Monday, March 1, 2021
Branches of biology, Health, Rare diseases, Collagen disease, Maple syrup urine disease, Celiprolol, Acer, Collagen, Sodium phenylbutyrate, Ehlers–Danlos syndromes, Ehlers, Maple

Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs.

Key Points: 
  • Acer is a pharmaceutical company focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs.
  • Acers pipeline includes four programs: ACER-001 (sodium phenylbutyrate) for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD); EDSIVO (celiprolol) for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms (iVMS); and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19.
  • Each of Acers product candidates is believed to present a comparatively de-risked profile, having one or more of a favorable safety profile, clinical proof-of-concept data, mechanistic differentiation and/or accelerated paths for development through specific programs and procedures established by the FDA.
  • For more information, visit www.acertx.com .

Acer Therapeutics Announces Publication of Vascular Ehlers-Danlos Syndrome (vEDS) Patient Registry Data from Sweden

Retrieved on: 
Thursday, December 17, 2020
Collagen disease, Contortion, Celiprolol, Ureas, Anatomy, Branches of biology, Medical specialties, Ehlers

The publication, entitled Celiprolol Treatment in Patients with Vascular Ehlers-Danlos Syndrome,1 can be found at https://www.ejves.com/action/showPdf?pii=S1078-5884%2820%2930930-8 .

Key Points: 
  • The publication, entitled Celiprolol Treatment in Patients with Vascular Ehlers-Danlos Syndrome,1 can be found at https://www.ejves.com/action/showPdf?pii=S1078-5884%2820%2930930-8 .
  • Patients were followed for a median of 22 months (range 1-98 months) with a total follow up of 106 patient years.
  • Sixty-five percent of the patients reached the target dose of 400 mg and the medication was generally well tolerated.
  • Effect of celiprolol on prevention of cardiovascular events in vascular Ehlers-Danlos syndrome: a prospective randomised, open, blinded-endpoints trial.

Intellicheck Appoints New Vice President of Sales

Retrieved on: 
Thursday, October 22, 2020
Technology, Finance, Security, Banking, Other Technology, Professional services, Software, Data management, Other Professional Services, Ehlers, Lluís Companys, Spanish politicians, Government of Spain

Intellicheck, Inc. (Nasdaq: IDN), an industry leader in identification authentication solutions, today announced the appointment of Michael Ehlers as the Companys new Vice President of Sales.

Key Points: 
  • Intellicheck, Inc. (Nasdaq: IDN), an industry leader in identification authentication solutions, today announced the appointment of Michael Ehlers as the Companys new Vice President of Sales.
  • Intellicheck CEO Bryan Lewis said, Mike brings a track record of leadership, team building and extensive business experience that we believe is critical to drive Intellicheck to the next level.
  • Prior to joining Intellicheck, Ehlers has spent the last fifteen years building high performance sales and management teams for fintech and software companies in his role as founder of Ehlers Recruiting Partners.
  • Commenting on the departure of Vice President of Sales Paul Fisher, Lewis said, We appreciate Pauls service to the Company, and we wish him well in his future endeavors.

1Q Hires Scott Ehlers as Chief Product Officer to Lead Product Development

Retrieved on: 
Monday, August 31, 2020
Ehlers, Danowski, 1Q

ATLANTA, Aug. 31, 2020 /PRNewswire/ --Today 1Q ( www.1Q.com ), a leading market research and customer engagement platform, announced Scott Ehlers joined as Chief Product Officer to lead product development, user experience, and quality assurance for the Atlanta-based start-up.

Key Points: 
  • ATLANTA, Aug. 31, 2020 /PRNewswire/ --Today 1Q ( www.1Q.com ), a leading market research and customer engagement platform, announced Scott Ehlers joined as Chief Product Officer to lead product development, user experience, and quality assurance for the Atlanta-based start-up.
  • Prior to joining 1Q, Ehlers had a long career as a product management executive for technology platforms.
  • I'm excited to join the team as 1Q continues to scale," said Scott Ehlers.
  • Ehlers joins Doug Danowski, 1Q's Chief Revenue Officer, as the start-up's most recent hires.

Colangelo & Partners Named Agency of Record for Napa Valley's Ehlers Estate

Retrieved on: 
Friday, August 28, 2020
Colangelo, Ehlers, Napa Valley AVA, Amplify, California

NEW YORK, Aug. 28, 2020 /PRNewswire-PRWeb/ -- Ehlers Estate , one of Napa Valley's most esteemed and historic wineries, has announced Colangelo & Partners as its agency of record in the United States.

Key Points: 
  • NEW YORK, Aug. 28, 2020 /PRNewswire-PRWeb/ -- Ehlers Estate , one of Napa Valley's most esteemed and historic wineries, has announced Colangelo & Partners as its agency of record in the United States.
  • Colangelo & Partners will focus the campaign on strategic media and trade relations to increase Ehlers Estate brand visibility as well as support selling opportunities.
  • "We're excited to amplify the awareness around these wines and the compelling Ehlers Estate story through our partnership with Colangelo & Partners."
  • "We're thrilled to add Ehlers Estate to our portfolio," says Gino Colangelo, president of Colangelo & Partners.

Shareholder Alert: Robbins LLP Is Investigating the Officers and Directors of Acer Therapeutics Inc. (ACER)

Retrieved on: 
Thursday, July 9, 2020
Legal, Professional services, Celiprolol, Ureas, Anatomy, Ehlers–Danlos syndrome, Collagen disease, Ehlers, Contortion, Acer Inc., Acer, Fiduciary, Organ systems, Medical specialties

Shareholder rights law firm Robbins LLP announces that it is investigating the officers and directors of Acer Therapeutics Inc. (NYSE: ACER) for breaches of fiduciary duty, waste of corporate assets, unjust enrichment, and violations of the Securities Exchange Act of 1934.

Key Points: 
  • Shareholder rights law firm Robbins LLP announces that it is investigating the officers and directors of Acer Therapeutics Inc. (NYSE: ACER) for breaches of fiduciary duty, waste of corporate assets, unjust enrichment, and violations of the Securities Exchange Act of 1934.
  • Acer is a pharmaceutical company that focuses on the development and commercialization of therapies for rare diseases.
  • One of its medications is EDVISO (celiprolol) for the treatment of vascular Ehlers-Danlos Syndrome ("vEDS").
  • To help fund this research, Acer conducted two secondary public offerings in December 2017 and August 2018.

The Law Offices of Frank R. Cruz Announces Investigation on Behalf of Acer Therapeutics Inc. Investors (ACER)

Retrieved on: 
Wednesday, June 24, 2020
Legal, Professional services, Business, Companies, Articles, Ehlers–Danlos syndrome, Common law, Equity, Fiduciary, Collagen disease, Ehlers, Board of directors, Acer Inc.

The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Acer Therapeutics Inc. (Acer or the Company) (NASDAQ: ACER ) concerning whether the board breached its fiduciary duties to shareholders.

Key Points: 
  • The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Acer Therapeutics Inc. (Acer or the Company) (NASDAQ: ACER ) concerning whether the board breached its fiduciary duties to shareholders.
  • According to the CRL, an adequate and well-controlled trial was required to determine whether EDSIVO reduces the risk of clinical events in patients with vascular Ehlers-Danlos syndrome.
  • On this news, the Companys share price fell $15.16, or nearly 79%, to close at $4.12 on June 25, 2019, thereby injuring investors.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

The Sullivan Group and The VEDS Movement Collaborate to Increase VEDS Awareness & Diagnosis

Retrieved on: 
Tuesday, March 24, 2020
Medicine, Medical specialties, Anatomy, Ehlers–Danlos syndrome, Collagen disease, Contortion, Ehlers–Danlos syndromes, RTT, Triage, Ehlers

This lack of familiarity frequently leads to delays and errors in the triage, evaluation, diagnosis and treatment of patients with VEDS and its complications.

Key Points: 
  • This lack of familiarity frequently leads to delays and errors in the triage, evaluation, diagnosis and treatment of patients with VEDS and its complications.
  • It is estimated that there are about 6,000 people in the U.S. with VEDS, although many are undiagnosed.
  • Many individuals with VEDS are not diagnosed until they have a life-threatening event, and 80% of VEDS patients will experience a major medical event by age 40.
  • The VEDS movement is dedicated to saving lives and improving the quality of life of individuals with Vascular Ehlers-Danlos Syndrome through research, patient support, education and awareness.

Agency Veteran Launches The Tease: A Digital Media Brand Aimed To Disrupt The Beauty & Salon Professional Industry

Retrieved on: 
Monday, January 20, 2020
Ehlers

Kelly Ehlers , female founder behind Ideas That Evoke and The Evoke Agency , channeled her insider knowledge of the digital marketing, beauty and salon professional industries to unveil this new take on trade media.

Key Points: 
  • Kelly Ehlers , female founder behind Ideas That Evoke and The Evoke Agency , channeled her insider knowledge of the digital marketing, beauty and salon professional industries to unveil this new take on trade media.
  • "Growing up quite literally in the back of my mother's small-town-Iowa salon, you could say I got my second education in the professional beauty industry," says Ehlers.
  • "Since then, I've spent my career working with many of the world's top beauty and salon professional brands.
  • With The Tease's coverage of industry news , beauty trends and more, Ehlers will revive a genuine conversation about beauty.